397 related articles for article (PubMed ID: 25923819)
1. Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction.
Brogan SE; Winter NB; Okifuji A
Reg Anesth Pain Med; 2015; 40(4):369-75. PubMed ID: 25923819
[TBL] [Abstract][Full Text] [Related]
2. Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary.
Brogan SE; Winter NB
Pain Med; 2011 Dec; 12(12):1758-68. PubMed ID: 22054042
[TBL] [Abstract][Full Text] [Related]
3. Cost Savings of Patient-Controlled Intrathecal Analgesia.
Bolash RB
Reg Anesth Pain Med; 2015; 40(5):639-40. PubMed ID: 26288036
[No Abstract] [Full Text] [Related]
4. Intrathecal Analgesia via a Percutaneous Port With Patient-Controlled Intrathecal Analgesia for the Management of Movement-Evoked Breakthrough Cancer Pain of Refractory Lower Extremity Cancer Pain: A Retrospective Review.
Zhou L; Guo Z
Pain Physician; 2023 Jul; 26(4):375-382. PubMed ID: 37535777
[TBL] [Abstract][Full Text] [Related]
5. Patient-Controlled Intravenous Analgesia for Advanced Cancer Patients with Pain: A Retrospective Series Study.
Peng Z; Zhang Y; Guo J; Guo X; Feng Z
Pain Res Manag; 2018; 2018():7323581. PubMed ID: 29849846
[TBL] [Abstract][Full Text] [Related]
6. Prospective Association of Serum Opioid Levels and Clinical Outcomes in Patients With Cancer Pain Treated With Intrathecal Opioid Therapy.
Brogan SE; Sindt JE; Jackman CM; White J; Wilding V; Okifuji A
Anesth Analg; 2020 Apr; 130(4):1035-1044. PubMed ID: 31206429
[TBL] [Abstract][Full Text] [Related]
7. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit.
Brogan SE; Winter NB; Abiodun A; Safarpour R
Pain Med; 2013 Apr; 14(4):478-86. PubMed ID: 23461787
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Patient-Controlled Intravenous Analgesia with Esketamine for Herpes Zoster Associated with Breakthrough Pain.
Tang J; Zhang E; Huang B; Fei Y; Yao M
Pain Physician; 2023 May; 26(3):299-306. PubMed ID: 37192235
[TBL] [Abstract][Full Text] [Related]
9. Iontophoretic transdermal system using fentanyl compared with patient-controlled intravenous analgesia using morphine for postoperative pain management.
Grond S; Hall J; Spacek A; Hoppenbrouwers M; Richarz U; Bonnet F
Br J Anaesth; 2007 Jun; 98(6):806-15. PubMed ID: 17519263
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: A prospective cohort study.
Zheng S; He L; Yang X; Li X; Yang Z
Medicine (Baltimore); 2017 Mar; 96(11):e6354. PubMed ID: 28296770
[TBL] [Abstract][Full Text] [Related]
11. Movement-evoked breakthrough cancer pain despite intrathecal analgesia: a prospective series.
Bäckryd E; Larsson B
Acta Anaesthesiol Scand; 2011 Oct; 55(9):1139-46. PubMed ID: 22092213
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; David F; Mangione S
Clin J Pain; 2007; 23(9):793-8. PubMed ID: 18075407
[TBL] [Abstract][Full Text] [Related]
13. Analgesia after Cesarean delivery: a retrospective comparison of intrathecal hydromorphone and morphine.
Beatty NC; Arendt KW; Niesen AD; Wittwer ED; Jacob AK
J Clin Anesth; 2013 Aug; 25(5):379-383. PubMed ID: 23965210
[TBL] [Abstract][Full Text] [Related]
14. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain.
Rauck RL; Cherry D; Boyer MF; Kosek P; Dunn J; Alo K
J Pain; 2003 Oct; 4(8):441-7. PubMed ID: 14622664
[TBL] [Abstract][Full Text] [Related]
15. [Effects of patient-controlled intravenous analgesia using hydromorphone supplement with dexmedetomidine on patients undergoing transcatheter arterial chemoembolization].
Wang HW; Li LL; Li ZS; Cheng LN
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):626-630. PubMed ID: 30139035
[No Abstract] [Full Text] [Related]
16. Clinical effectiveness and safety of OROS® hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients.
Lee KH; Kim MK; Hyun MS; Kim JY; Park KU; Song HS; Lee SA; Lee WS; Bae SH; Ryoo HM; Cho YY
J Opioid Manag; 2012; 8(4):243-52. PubMed ID: 22941852
[TBL] [Abstract][Full Text] [Related]
17. Cost comparison of intrathecal morphine to intravenous patient-controlled analgesia for the first 24 h post cesarean delivery: a retrospective cohort study.
Patel N; Bryant A; Duncan K; Kukreja P; Powell MF
J Anesth; 2017 Feb; 31(1):44-50. PubMed ID: 27743120
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of continuous wound infiltration for postoperative pain management after open gastrectomy.
Zheng X; Feng X; Cai XJ
World J Gastroenterol; 2016 Feb; 22(5):1902-10. PubMed ID: 26855550
[TBL] [Abstract][Full Text] [Related]
19. Neuraxial opioids for post-cesarean delivery analgesia: can hydromorphone replace morphine? A retrospective study.
Marroquin B; Feng C; Balofsky A; Edwards K; Iqbal A; Kanel J; Jackson M; Newton M; Rothstein D; Wong E; Wissler R
Int J Obstet Anesth; 2017 May; 30():16-22. PubMed ID: 28185794
[TBL] [Abstract][Full Text] [Related]
20. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.
Enting RH; Oldenmenger WH; van der Rijt CC; Wilms EB; Elfrink EJ; Elswijk I; Sillevis Smitt PA
Cancer; 2002 Jun; 94(11):3049-56. PubMed ID: 12115396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
